Objective of the trial is to study if famotidine add-on treatment is more effective than
placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient
response to ongoing antipsychotic treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Jesper Ekelund
Collaborators:
Ahokas foundation, Finland City of Helsinki Karolinska Institutet Region Stockholm Social services and Healthcare, City of Helsinki, Finland Stanley Medical Research Institute Stockholm County Council, Sweden